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Heme is an essential cofactor required for a plethora of cellular processes in eukaryotes. In metazoans the heme
biosynthetic pathway is typically partitioned between the cytosol and mitochondria, with the first and final steps
taking place in the mitochondrion. The pathway has been extensively studied and its biosynthetic enzymes
structurally characterized to varying extents. Nevertheless, understanding of the regulation of heme synthesis
and factors that influence this process in metazoans remains incomplete. Therefore, we investigated the mo
lecular organization as well as the physical and genetic interactions of the terminal pathway enzyme, ferro
chelatase (Hem15), in the yeast Saccharomyces cerevisiae. Biochemical and genetic analyses revealed dynamic
association of Hem15 with Mic60, a core component of the mitochondrial contact site and cristae organizing
system (MICOS). Loss of MICOS negatively impacts Hem15 activity, affects the size of the Hem15 high-mass
complex, and results in accumulation of reactive and potentially toxic tetrapyrrole precursors that may cause
oxidative damage. Restoring intermembrane connectivity in MICOS-deficient cells mitigates these cytotoxic ef
fects. These data provide new insights into how heme biosynthetic machinery is organized and regulated, linking
mitochondrial architecture-organizing factors to heme homeostasis.

1. Introduction
Heme is an essential cofactor and signaling molecule required for
diverse physiological processes, from the mitochondrial electron trans
port chain to oxygen transportation through the bloodstream [1–4].
Most metazoans synthesize heme through a highly conserved and

well-characterized eight-step pathway [5]. In the first step, the mito
chondrial enzyme aminolevulinic acid synthase (Alas; ALAS in humans;
Hem1 in yeast) catalyzes the condensation of glycine and succinyl-CoA
to form aminolevulinic acid (ALA), which is then transported out of the
mitochondrion by an as-yet-uncharacterized transporter. Once in the
cytosol, two ALA molecules are condensed into a monopyrrole,
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porphobilinogen, by the enzyme porphobilinogen synthase (Pbgs);
subsequently, four porphobilinogen molecules are joined together by
hydroxymethylbilane synthase (Hmbs) to form the linear tetrapyrrole
hydroxymethylbilane (HMB). HMB then undergoes cyclization to form
uroporphyrinogen III (catalyzed by uroporphyrinogen synthase, Uros)
and decarboxylation of its pyrrole acetate side chains (catalyzed by
uroporphyrinogen decarboxylase, Urod) to yield coproporphyrinogen
III. In Saccharomyces cerevisiae, coproporphyrinogen III is converted to
protoporphyrinogen IX by coproporphyrinogen oxidase (Cpox) in the
cytosol [6,7], while in humans this reaction occurs in the mitochondrial
intermembrane space (IMS) [8,9].
Protoporphyrinogen IX is transported into the mitochondrial matrix
and converted to protoporphyrin IX (PPIX) by the matrix-localized
enzyme protoporphyrinogen oxidase (Ppox) [10]. How proto
porphyrinogen IX is transported across the inner mitochondrial mem
brane (IM) is currently unclear though evidence suggests that the
porphyrinogen transporter TMEM14C facilitates this process during
erythroid cell maturation [11]. The final step of heme synthesis is
catalyzed by ferrochelatase (Fech; FECH in humans; Hem15 in yeast),
which resides on the matrix side of the IM [12] and mediates the
insertion of ferrous iron into PPIX, thereby yielding heme (also known as
protoheme or heme b).
Even though the proteins involved in heme synthesis have been
structurally characterized and in some cases examined mechanistically
[3,13], the processes by which the relative rates of heme synthesis are
regulated remain obscure. Understanding of this regulation is mainly
limited to the transcriptional level in multicellular organisms with
erythrocytes. In these organisms, most heme production occurs in the
developing erythron, and specific transcription factors are known to
play a role in regulating expression of all the biosynthetic enzymes [14].
The mechanisms of regulation of heme synthesis for many other cells in
these organisms and in unicellular eukaryotes like S. cerevisiae, all of
which require less heme, remain uncharacterized.
In terms of enzyme activity, the rate-limiting step of the pathway in
mammals is the first step (catalyzed by ALAS), with the last step (cata
lyzed by FECH) being the second regulatory point of the mammalian
pathway [14]. In S. cerevisiae, two other pathway enzymes, Pbgs and
Hmbs, have been proposed to catalyze the rate-limiting steps [7,15].
Recent data suggest additional levels of regulation at the
post-translational level [16,17].
Proteomic studies in mammalian cells show that the mitochondrial
heme biosynthetic machinery exists as a large supercomplex, termed the
heme metabolon [17–19]. FECH was identified as a component of a
multimeric assembly that includes ALAS and PPOX, the porphyrinogen
transporter TMEM14C, and succinyl-CoA synthase [17,18]. The mito
chondrial iron importer mitoferrin [20] and two ATP-binding cassette
proteins (ABCB7 and ABCB10) [20–22] have also been shown to bind to
FECH. Additional candidate interaction partners of FECH include factors
that mediate IM dynamics and ultrastructure [17,19], most notably
components of the conserved mitochondrial contact site and cristae
organizing system (MICOS). As suggested by its name, MICOS maintains
mitochondrial cristae and contact sites between the IM and the outer
mitochondrial membrane (OM) [23–25] and has been postulated to
facilitate bidirectional transport of hydrophobic molecules such as
phosphatidic acid [26] and coenzyme Q biosynthetic intermediates
[27]. However, the physiological significance of its connection to FECH
remains unaddressed.
Here, a yeast genetic model was employed to investigate the putative
molecular interaction of Fech (Hem15 in yeast) with MICOS. Data from
biochemical and genetic analyses are consistent with a dynamic asso
ciation of Hem15 with the core MICOS component Mic60. Loss of MICOS
negatively impacts Hem15 activity and results in accumulation of
cytotoxic pathway intermediates. These data provide insights into how
the heme biosynthetic machinery is organized and supported, linking
mitochondrial architecture to heme homeostasis.

2. Results
2.1. Functional Hem15 forms a high-mass complex
Hem15 is known to exist as a homodimer [28,29], but its pro
tein− protein interaction has not been systematically studied. To that
end, an antibody was developed against Hem15, which specifically
recognizes S. cerevisiae Hem15 (Fig. 1A). Using this antibody and puri
fied Hem15 as a reference, mitochondria from galactose-cultured wild
type (WT) cells in the mid-log growth phase were found to contain
approximately 1.0 ng of endogenous Hem15 per milligram of mito
chondrial protein (Supplementary Fig. S1A). This concentration is
comparable to other mitochondrial heme synthesis enzymes as well as
other IM proteins [30]. To assess the oligomerization state of Hem15,
mitochondria from WT cells were lysed with digitonin and the lysate
proteins subjected to sucrose gradient ultracentrifugation followed by
SDS-PAGE immunoblotting of the gradient fractions. Hem15 was
detected in the ~250–440 kDa molecular weight range (Fig. 1B), sug
gesting that endogenous yeast Hem15 exists as a high-mass complex,
which likely includes additional associated components, as seen for the
mammalian enzyme [17].
To determine whether the formation of this complex depends on the
functional state of Hem15, the same analysis was performed using a
catalytically impaired Hem15 variant, H235C. The yeast Hem15 residue
H235 is equivalent to the human FECH residue H263, which is an
essential catalytic histidine involved in proton abstraction prior to
chelation [31]. Conversion of this residue to a cysteine yielded a variant
that is stably expressed yet unable to support heme-independent growth
or exhibit in vitro Fech activity (Supplementary Figs. S1B and S1C).
While WT Hem15 predominantly copurifies with bound heme, the
H235C variant protein copurifies with PPIX (Supplementary Fig. S1D),
further demonstrating this variant of Hem15 is impaired in catalyzing
formation of heme from PPIX substrate. This H235C variant was found
in fractions of lower molecular weight when mitochondrial lysates were
subjected to sucrose gradient ultracentrifugation (Fig. 1B), suggesting
the formation of the full complex is impaired when Hem15 is catalyti
cally inactive. The Hem15 complex was also found to shift to lower
molecular weight fractions in gradient ultracentrifugation of mito
chondrial lysates derived from heme synthesis-deficient cells lacking
Alas (yeast Hem1; Fig. 1B). These findings suggest that Hem15 oligo
merization is at least partially dependent on the functional state of both
Hem15 and an earlier step of the heme biosynthetic pathway.
2.2. Human ferrochelatase complements the yeast deletion strain
Human FECH was discovered to be fully functional in yeast, com
plementing the yeast hem15Δ deletion mutant (Fig. 2A), which cannot
survive in the absence of exogenous heme supplementation. This finding
reveals that essential interactions between Fech and other proteins are
conserved in S. cerevisiae. This result is also interesting because there are
known differences between the yeast and human ferrochelatase en
zymes. The human enzyme, but not the yeast enzyme, possesses a
[2Fe–2S] cluster, which is required for enzyme activity [32–34].
Complementation of the hem15Δ strain with wild-type human FECH,
but not the human FECH variant C406S lacking an essential [32,35]
cluster ligand residue (Fig. 2A), suggests that the FECH iron-sulfur
cluster is assembled properly in yeast.
2.3. A genetic model was developed to assess Hem15 functional roles
While re-expression of either yeast or human ferrochelatase (under
the control of the native yeast ferrochelatase promoter or a constitutive,
high-efficiency MET25 promoter, both on a YEp vector) in the yeast
hem15Δ strain allows cell growth in the presence of glucose, it does not
always permit growth of this strain on respiratory media (Fig. 2B). This
phenomenon has been observed previously [36] and has thus far posed
2
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Fig. 1. Functional Hem15 forms a highmass complex. (A) Isolated mitochondria
(15 μg total protein) from wild type (WT)
and hem15Δ cells overexpressing Hem15
(from the HEM15 promoter) or expressing a
vector control were subjected to SDS-PAGE
and analyzed by immunoblotting with anti
bodies against Hem15 and the outer mito
chondrial membrane protein porin (loading
control). (B) High-velocity density-gradient
fractionation of digitonin-solubilized lysates
from mitochondria of hem1Δ cells or hem15Δ
cells expressing Hem15 or its H235C cata
lytically impaired variant, analyzed by SDSPAGE with immunoblotting for Hem15 and
porin (440-kDa molecular size reference).

Fig. 2. Human ferrochelatase is fully
functional in yeast, and loss of Hem15
results in a petite-inducing phenotype
that can be reversed by overexpression of
ribonucleotide reductase. (A) Hemedependent growth test of WT cells and
hem15Δ cells expressing vector control
(vector), yeast ferrochelatase (HEM15),
human ferrochelatase (FECH), or the C406S
variant of human ferrochelatase (FECH
C406S). Cells were spotted onto SC medium
with (+Heme) or without (- Heme) 20 μM
hemin and cultured for 2 days at 28oC. (B)
Heme-dependent fermentative and respira
tory growth test of WT cells or hem15Δ cells
expressing vector control (vector), Rnr1
(RNR1 ↑), Hem15 under control of its native
promoter (HEM15 ↑), or co-expressing Rnr1
and Hem15. Cells were spotted onto SC
media with or without 20 μM hemin and
cultured for 2 days (glucose) or 5 days
(glycerol/lactate) at 28oC. (C) SDS-PAGE
immunoblot showing steady-state levels of
three proteins encoded by the mitochondrial
genome (Cox1, Cox2, and Cox3) with aconi
tase loading control (Aco1), in mitochondria
from cells described in panel B.

an obstacle to further in-depth functional studies of Hem15.
This inability of plasmid borne HEM15 to complement the hem15Δ
deletion mutant was hypothesized to be due to the hem15Δ strain
becoming petite, i.e., mitochondrial DNA is lost upon deletion of the
HEM15 gene. Consistent with this interpretation, employing a known
strategy to stabilize the mitochondrial genome resolved this obstacle.
Overexpression of the dNTP checkpoint enzyme Rnr1, which encodes
the large subunit of ribonucleotide reductase, has previously been very
effective to stabilize mitochondrial DNA in various petite mutants via an
unknown mechanism [37–39]. Employing this strategy in hem15Δ cells
following Hem15 re-expression using a YEp vector under the control of
its native promoter (HEM15↑) or a constitutive, high-efficiency MET25
promoter (HEM15↑↑) restored respiratory growth (Fig. 2B), returned
both respiratory complexes and their subunit proteins to WT levels, and
permitted complementation with human FECH (Fig. 2C; Supplementary
Fig. S2).

2.4. Hem15 is physically associated with MICOS machinery
Protein interaction partners of Hem15 were determined by immu
noprecipitation (IP) of a FLAG-tagged Hem15 construct. Since attach
ment of a C-terminal tag to FECH results in an inactive enzyme [40],
Hem15 was tagged immediately after its N-terminal mitochondrial tar
geting sequence, so that the natural proteolytic removal of the targeting
sequence upon mitochondrial import results in a protein bearing the
FLAG tag on the structurally disordered amino terminus (Supplementary
Fig. S3A). This Hem15-iFLAG construct is stably expressed and func
tional (Supplementary Figs. S3B and S3C) and was therefore used for IP
experiments.
Clarified mitochondrial lysates from hem15Δ cells stabilized with
Rnr1 and expressing Hem15-iFLAG were incubated with anti-FLAG af
finity resin, and affinity-purified proteins were analyzed by LC-MS/MS
to identify co-purifying proteins. In addition to Hem15 and some of its
previously known binding partners such as Ppox (Hem14) [17], the IM
3
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GTPase Mgm1 and five of the eight known subunits of the MICOS
complex (Mic60, Mic19, Mic26, Mic27, and Mic12) were all identified as
physically interacting with Hem15 (Fig. 3A). Consistent with these
findings, targeted co-IP experiments showed the core MICOS subunit
Mic60 co-purifies with Hem15-iFLAG (Fig. 3B), further suggesting
physical association between Hem15 and MICOS. These findings are
consistent with interactions observed in IP experiments with yeast
MICOS [41] and human FECH [17,19].
To examine the functional significance of this Hem15-MICOS asso
ciation, the impact of MIC60 deletion on Hem15 was experimentally
determined. Steady-state levels of Hem15 were not affected in the
mic60Δ deletion mutant (Supplementary Fig. S3D). However, the su
crose gradient migration profile of the Hem15 high-mass complex
derived from mic60Δ mutant mitochondria was altered, indicating a
shift toward smaller complex size (Fig. 3C). This shift in Hem15 olig
omer fractionation pattern is similar to that observed for both the
nonfunctional H235C Hem15 variant and WT Hem15 in the hem1Δ
mutant (Fig. 1B). Collectively, these results suggest that Hem15 asso
ciates with the MICOS complex and Hem15 oligomerization is impaired
in the absence of MICOS.

2.5. MICOS facilitates proper heme biosynthetic activity of Hem15
Respiratory growth in the absence of Mic60 was observed to be
slightly impaired, and this growth defect enhanced markedly when
Hem15 levels were elevated by overexpression from a plasmid (Fig. 4A).
This result was observed for mic60Δ strains in both the W303 and
BY4741 genetic backgrounds and with plasmids expressing Hem15 from
either its native promoter or a strong heterologous promoter. Hem15
protein levels remained similar in the presence versus the absence of
Mic60 (Fig. 4B), ruling out reduced levels of Hem15 as a possible cause
for the growth defect. Therefore, the activity of that Hem15 protein was
examined.
WT and mic60Δ cell lysates do not have significantly different levels
of Fech activity, and overexpression of Hem15 in each cell type results in
significantly increased PPIX metalation by Hem15 (Fig. 4C). Strikingly,
when Hem15 is overexpressed, mic60Δ cells have dramatically lower
Fech activity than WT cells, suggesting an inability to maximize heme
production in the absence of Mic60 despite abundant Hem15 protein
(Fig. 4B and C). This apparent defect in Hem15 activity in the absence of
Mic60 raises questions about the role of MICOS in the function of
Hem15, which were pursued next.
Fig. 3. Hem15 physically interacts with MICOS.
(A) Table and schematic summarizing LC-MS/MS
identification of immunoprecipitated proteins from
mitochondrial lysates of hem15Δ cells expressing
Hem15-iFLAG. Identified components of the MICOS
machinery are color-coded to reflect the abundance
of peptides corresponding to each identified sub
unit. Table shows representative data of two inde
pendent
biological
replicates.
(B)
Coimmunoprecipitation of Hem15-iFLAG and the
endogenous Mic60 core subunit of MICOS.
Digitonin-solubilized mitochondrial lysates from
hem15Δ cells expressing Rnr1 and co-expressing
either Hem15-iFLAG or empty vector control were
incubated with anti-FLAG affinity resin; following
the incubation, samples were subjected to SDSPAGE and analyzed by immunoblotting with indi
cated antibodies. The blots show 10% of mitochon
drial lysate fractions before (Load, Pre) and after
(Load, Post) pre-clearance with IgG agarose beads,
the unbound fraction after incubation with antiFLAG affinity resin (Unbound), the whole precipi
tated fraction from the final wash (Wash), and half
of the eluted fraction (Bound). (C) Sucrose density
gradient ultracentrifugation of digitonin-solubilized
Hem15 complexes from mitochondria of WT and
mic60Δ cells, analyzed as in Fig. 1B. Asterisk marks
nonspecific bands. (For interpretation of the refer
ences to color in this figure legend, the reader is
referred to the Web version of this article.)
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Fig. 4. Hem15 activity is impaired in the
absence of MICOS. (A) Fermentative and
respiratory growth of WT and mic60Δ cells
expressing vector control or Hem15 under
control of its native promoter (HEM15 ↑) or
the heterologous MET25 promoter (HEM15
↑↑). Cells were spotted onto SC media and
cultured for 2 days (glucose), 3 days (galac
tose), or 5 days (glycerol/lactate) at 28oC.
(B) SDS-PAGE immunoblot of indicated
proteins in mitochondria from cells described
in panel A. (C) Ferrochelatase specific activ
ity in mitochondrial lysates from indicated
cells. Bars indicate the average and S.D.
(error bars) of 3 biological replicates. Aster
isks indicate a statistically significant differ
ence by t-test (***p < 0.001).

2.6. MICOS is required for optimal porphyrin substrate delivery to Hem15

rates of heme trafficking from the matrix side of the mitochondrial IM
(where the active site of Fech is located) to the locale of HS1. This assay
revealed that hemylation rates of cytosol- and mitochondrial
matrix-targeted HS1 in the mic60Δ mutant were comparable to those
seen in WT cells, indicating that there is no significant dependence of
heme export on MICOS, either directly or indirectly (Fig. 5A). Consistent
with this finding, total heme levels measured by UPLC were not signif
icantly different in the presence versus the absence of Mic60 (Fig. 5B).
To investigate the possibility that loss of MICOS impairs the import
of substrates of either Hem15 or other enzymes in the heme biosynthetic
pathway, levels of mitochondrial iron and cellular porphyrins were
measured. The iron content measured by ICP-MS was comparable in
highly purified mitochondrial fractions from WT and mic60Δ cells with
or without Hem15 overexpression (Supplementary Fig. S4A), ruling out
iron deficiency as the reason for reduced Fech activity in the Hem15overexpressing mic60Δ mutant. In agreement with this result, the
steady-state levels of the mitochondrial iron transporter Mrs3 were also
unchanged by the absence of Mic60 (Supplementary Fig. S4B). Likewise,
loss of Mic60 had no appreciable effect on the activity of the iron-sulfur
cluster-containing enzyme succinate dehydrogenase, indicating that
iron-sulfur cluster biogenesis is not affected (Supplementary Fig. S4C).
To test the availability of the other substrate for Fech, PPIX, and
intermediates necessary for its synthesis, cellular porphyrin content was
analyzed in cells lacking Mic60. Spectroscopy revealed that total
porphyrin fluorescence is increased in mic60Δ cells compared to WT
(Supplementary Fig. S4D). UPLC was then employed to separate por
phyrins to determine which types were causing this elevated fluores
cence. The porphyrins analyzed are the oxidized products of the
pathway intermediates, which are porphyrinogens. This detailed
porphyrin profiling revealed a ~3-fold increase in total intermediate
porphyrins in mic60Δ cells compared to WT cells (Fig. 5C) and showed
that the proportions of the 8-, 7-, 6-, 5-, and 4-COOH porphyrins were

MICOS could potentially impact Hem15 activity either directly or
indirectly. MICOS could be directly responsible for substrate import into
or heme export out of mitochondria due to its key role in maintenance of
IM-OM contact sites [24,25], which are postulated to facilitate bidi
rectional transport of hydrophobic molecules (e.g., phosphatidic acid
and coenzyme Q biosynthetic intermediates) [26,27]. Alternatively, the
disorganization of the IM stemming from loss of MICOS could negatively
impact mitochondrial carrier proteins required for import of substrates
or export of heme, thus indirectly impacting Hem15.
In either the direct or indirect involvement scenario, 1) impaired
heme export due to the absence of MICOS might lead to mitochondrial
heme build-up and inhibition of Hem15 by heme [42], since heme
dissociation from Fech is the rate-limiting step in catalysis [43], or 2)
impaired import of substrates and intermediates required for heme syn
thesis into mitochondria might limit substrate availability to Fech. To
investigate these two potential mechanisms for how the MICOS ma
chinery contributes to Fech activity, experiments were carried out to
assess rates of heme transport across the IM, cellular heme levels,
mitochondrial iron levels, and cellular levels of porphyrin biosynthetic
precursors to heme, including PPIX.
To investigate the possibility that loss of MICOS impairs heme
export, both rates of heme transport across the IM and cellular heme
levels were determined. A high-affinity, genetically encoded heme
sensor (HS1) [44,45] was employed in an assay to compare rates of
heme transport across the IM in WT and mic60Δ cells. In this assay, heme
synthesis is blocked with succinylacetone, an inhibitor of the heme
synthetic enzyme Pbgs, and then reinitiated by removing the inhibitor
from the medium. The heme occupancy of mitochondrial matrix- and
cytosol-targeted HS1 is then monitored as a function of time [46]. In
principle, the rates of heme binding to the sensor reflect the relative
5
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Fig. 5. MICOS-deficient cells accumulate
reactive porphyrin biosynthetic pre
cursors. (A) Relative rates of heme binding
to the HS1 heme sensor in the mitochondrial
matrix (left) and cytosol (right), the latter of
which requires heme export across the IM,
upon re-initiation of heme synthesis in WT
and mic60Δ cells. Heme trafficking kinetics
data shown represent mean ± S.D. of inde
pendent triplicate cultures. (B–D) Heme, in
termediate (8-, 7-, 6-, 5-, and 4-COOH)
porphyrins, and protoporphyrin IX (PPIX)
levels in WT and mic60Δ cells with and
without Hem15 overexpression, analyzed by
UPLC. Bars indicate average ± S.D. (error
bars) of 4–5 biological replicates measured in
technical triplicates. Asterisks indicate a
statistically significant difference by t-test
(*p < 0.05, **p < 0.01, ***p < 0.001).

altered in these cells (Supplementary Fig. S5). To rule out the possibility
that metabolite transport is universally defective in mic60Δ cells,
mitochondrial lipoylation was measured in WT and mic60Δ cells. Levels
of the lipoylated mitochondrial pyruvate dehydrogenase subunit dihy
drolipoamide acetyltransferase and dihydrolipoyl succinyltransferase
were found to be normal in the absence of Mic60, suggesting IM carrier
proteins remain generally functional and the elevated porphyrins
observed in the absence of Mic60 are the result of a specific effect
(Supplementary Fig. S4E).
Interestingly, PPIX was decreased in mic60Δ cells overexpressing
Hem15 compared to WT cells overexpressing Hem15 (Fig. 5D), sug
gesting substrate availability may be a factor that limits Fech activity in
these cells. Much like the subtle growth defect and statistically insig
nificant decrease in Fech activity seen in mic60Δ cells compared to WT
cells with endogenous Hem15 levels (Fig. 4), levels of PPIX are not
significantly different in the presence versus the absence of Mic60 when
Hem15 is present at endogenous levels (Fig. 5D). However, when
Hem15 is overexpressed, the growth defect becomes marked, the
decrease in Fech activity becomes dramatic, and the decrease in levels of
PPIX becomes significant. These three experiments suggest a role for
MICOS in Hem15 activity that is more apparent under conditions of high
Hem15 levels, when PPIX may become limiting for Hem15 activity.

deficient cells could mitigate some of these cytotoxic effects, an artifi
cial IM-OM tether, mitoT, was generated [50] (Fig. 6D and E). This
chimeric protein comprises the N-terminal portion of the IM protein
Sco2 (residues 1–112) encompassing the mitochondrial targeting
sequence and transmembrane domain, followed by a short (12 amino
acid residues) unstructured linker derived from the E. coli LacI protein, a
transmembrane helix of the OM import receptor protein Tom20 (resi
dues 1–20), and the GFP moiety. The optimal length of the linker region
was deduced from the previously reported analogous construct [26].
Co-expression of mitoT in Hem15-overexpressing mic60Δ cells
improved growth on galactose and glycerol-lactate media, reflecting a
partial rescue effect (Fig. 6F). Interestingly, mitoT expression had the
opposite effect in Hem15-overexpressing WT cells, suggesting that
excess intermembrane tethering has a negative effect on the normal
function of mitochondria. MitoT expression also resulted in increased
steady-state levels of Hem15 protein in both WT and mic60Δ cells
(Fig. 6E) although the reason for this effect is unclear at present. The
rescue appears to be due to a remarkable increase in oxidative stress
tolerance in the Hem15-overexpressing mic60Δ cells co-expressing
mitoT (Fig. 6G).
3. Discussion
Towards the goal of better understanding the molecular and func
tional organization of yeast ferrochelatase (Hem15) and, more broadly,
the regulation of the heme biosynthetic pathway, this study has revealed
several new findings.
The functional state of Hem15 was assessed and the yeast enzyme
compared to human ferrochelatase. Hem15 assembles into a high-mass
oligomer, which likely represents the functional enzyme, as it is
compromised both in hem1Δ cells blocked at a very early stage of heme
biosynthesis and in cells expressing the catalytically inactive H235C
Hem15 mutant. This study confirmed that the yeast H235 residue is
critical for Fech activity in yeast, much like the homologous H263 res
idue in humans [31], and is similarly hypothesized to be critical for
proton abstraction from PPIX for metalation and heme formation.
To determine how the active-site structure of Hem15 is impacted by
the H235C mutation, the H235C variant was crystallized and its struc
ture solved at 2.4 Å resolution. This structure reveals that the location
and orientation of active-site residues in the WT protein and H235C
Hem15 variant are similar, as are the active-site hydrogen-bonding

2.7. MICOS-deficient cells expressing Hem15 have oxidative stress, which
can be partially mitigated by synthetic restoration of IM/OM contact sites
Since heme synthesis pathway intermediates like those elevated in
the absence of Mic60 are known to be toxic, in part due to their inherent
redox reactivity [5,47–49], signs of oxidative damage and stress were
evaluated in the absence of Mic60. The metabolic enzyme aconitase was
assessed first because of its sensitivity to damage by superoxide. While
steady-state levels of aconitase were the same in WT and mic60Δ cells
overexpressing Hem15 (Fig. S6), the cells lacking Mic60 exhibited a
significant decrease in aconitase specific activity, consistent with
oxidative damage (Fig. 6A). Furthermore, mic60Δ cells overexpressing
Hem15 were significantly less tolerant to acute oxidative insults than
WT cells overexpressing Hem15 (Fig. 6B). Consistent with these obser
vations of oxidative stress, supplementation with the antioxidant
N-acetylcysteine
partially
rescued
a
growth
defect
of
Hem15-overexpressing mic60Δ cells on galactose medium (Fig. 6C).
To test whether restoring intermembrane connectivity in MICOS6
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Fig. 6. MICOS-deficient cells expressing Hem15
exhibit oxidative stress that can be mitigated by
a synthetic intermembrane bridge. (A) Aconitase
enzymatic activity in mitochondria isolated from
WT and mic60Δ cells with and without Hem15
overexpression, harvested after 5 days in culture.
Bars indicate the average ± S.D. (error bars) of 3
biological replicates. Asterisks indicate a statisti
cally significant difference by one-way ANOVA with
Tukey’s post-hoc test (*p < 0.05). (B) Hydrogen
peroxide sensitivity of cells described in panel A.
Cells were cultured to mid-log phase, normalized,
and acutely treated with 1 mM hydrogen peroxide
for 1 h at 28oC. Following treatment, cultures were
diluted to 300 cells per sample and plated to assess
viable colony forming units after 48 h of growth at
28oC. Bars indicate the average ± S.D. (error bars)
of 4 biological replicates. Asterisks indicate a sta
tistically significant difference by one-way ANOVA
with Tukey’s posthoc test (*p < 0.05). (C) Growth
test of cells described in panel A with or without the
addition of 10 mM N-acetylcysteine (NAC), assessed
as in Fig. 4A. (D) Schematic depicting mitoT syn
thetic intermembrane tether. (E) SDS-PAGE immu
noblot analysis of mitochondria isolated from WT
and mic60Δ cells expressing vector controls, over
expressing Hem15 or mitoT, or overexpressing both
constructs simultaneously. Steady-state levels of
indicated proteins were visualized with appropriate
antibodies (anti-GFP antibody was used to detect
mitoT). The outer mitochondrial membrane protein
porin served as a loading control. (F) Growth test of
cells described in panel E, assessed as in Fig. 4A. (G)
Hydrogen peroxide sensitivity of cells described in
panel E, handled and analyzed as in panel B.

networks (Supplementary Fig. S1E). This intact network differs from the
human H263C variant structure where the network is disrupted [31]. It
is unclear why this difference between the yeast and human catalytic
mutants exists, though both variants are inactive due to the absence of
the base (H235 in yeast and H263 in humans) necessary for proton
abstraction.
Human FECH is able to efficiently replace the yeast enzyme, despite
the human enzyme requiring a [2Fe–2S] cluster for enzyme activity
[32–34] that is absent in the yeast enzyme. This iron–sulfur cluster is
believed to serve as a sensor for the redox state and/or pH of the
mitochondrial matrix [32,51]. The finding that WT human FECH, but
not a mutant bearing the C406S substitution for one of the

cluster-binding ligands, complements the yeast deletion mutant suggests
that the cluster is successfully formed in the context of yeast
mitochondria.
Hem15-deficient cells exhibit a petite-inducing phenotype that can
be rescued genetically through re-expression of Hem15 in conjunction
with overexpression of ribonucleotide reductase subunit Rnr1, a genetic
manipulation known to stabilize mitochondrial DNA in petite mutants
[39,52]. This finding explains previously described difficulties in
establishing a robust genetic complementation of the hem15Δ mutant
with plasmid-borne Hem15 [36]. While the exact molecular un
derpinnings of the petite-inducing phenotype of hem15Δ are currently
unclear, they might arise from impaired hemylation of mitochondrial
7
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matrix hemoproteins with connections to the mitochondrial genome,
such as the yeast flavohemoglobin Yhb1 or translational activator Mss51
[53–56]. Further studies are warranted to explore the connection be
tween loss of Hem15 and instability of mitochondrial DNA.
The high-mass Hem15 complex was found by proteomic analysis to
contain components of the MICOS machinery. A portion of the core
MICOS subunit Mic60 is exposed to the matrix side of the IM [24,25] and
is thus likely to mediate this Hem15-MICOS association. Loss of Mic60
affects the high-mass oligomeric species of Hem15 akin to the destabi
lizing effect of the catalytic H235C Hem15 variant and the Alas (Hem1)
deletion mutant, consistent with the idea that MICOS contributes to the
molecular organization of Fech. These results agree with earlier reports
suggesting that mammalian FECH is a component of a large complex
termed the mitochondrial heme metabolon [17–19]. Studies in
mammalian cells have shown the heme metabolon contains components
of MICOS, underscoring the conservation and importance of this
connection.
The yeast MICOS presents as a series of large oligomers [41] and,
since Mic60 is about 1.5-fold more abundant than Hem15 [30,57], it is
unlikely that its subunits form stable stoichiometric complexes with
Hem15. Instead, there may be a dynamic association between Hem15
and MICOS that is not essential for Hem15 activity but is nevertheless
important for its ideal performance. In agreement with this idea is the
observation that basal Hem15 activity is not significantly affected in the
mic60Δ mutant, whereas the added strain caused by overexpression of
Hem15 results in a profound respiratory growth defect, reduces levels of
PPIX, attenuates Hem15 activity, elevates levels of intermediate por
phyrins, and results in oxidative damage and stress, compared to simi
larly treated WT cells. Porphyrin profiling under these conditions
revealed that the levels of some porphyrins like coproporphyrins and
PPIX are decreased in the absence of Mic60, while others like hex
acarboxylporphyrins and heptacarboxylporphyrins are increased. Low
PPIX levels could be attributed to reduced Ppox activity, a downstream
effect of low Cpox activity since Cpox is inhibited by heme [58], or a
more complex result of this apparent disruption of porphyrin transport
and homeostasis. The elevated intermediate porphyrins are likely
causing the oxidative damage and stress observed when Hem15 is
overexpressed.
These results suggest the FECH-MICOS association has functional
significance. We propose a model wherein IM-OM contact sites formed
by MICOS facilitate the transfer of intermediate porphyrinogen pre
cursors across the mitochondrial membranes, thereby ensuring optimal
substrate delivery to Fech as well as PPOX (Fig. 7). Data in the current
study do not exclude the possibility that MICOS is directly involved in

this transport of heme biosynthetic intermediates, analogous to its
proposed role in transporting phospholipids such as phosphatidic acid
[26] and coenzyme Q biosynthetic intermediates [27]. However, it may
be more likely that MICOS plays an indirect role through one or more
plausible mechanisms. For instance, the complex may aid the heme in
termediate transport process through bridging the OM and IM to create a
proximity conduit between these membranes, as suggested by the rescue
of oxidative stress tolerance seen in Hem15-overexpressing mic60Δ cells
co-expressing a synthetic mitoT [50] tether. In mammalian cells, MICOS
might be required for spatial organization of the currently elusive cop
roporphyrinogen III and protoporphyrinogen IX transporters in the OM
and IM, respectively, thus accounting for the accumulation of tetra
pyrrole intermediates arising from cellular accumulation of the heme
synthesis intermediates during uroporphyrinogen III decarboxylation in
MICOS-deficient cells (Fig. 5C and Supplementary Fig. S5). It is unclear
under which conditions MICOS and Fech physically interact, but this
interaction is expected to be dynamic and transient, as discussed above.
Intriguingly, Mic60 is highly conserved with homologs found in
α-proteobacteria, wherein the gene clusters with heme biosynthetic
genes [59,60], further supporting a potential functional link between
MICOS and the heme biosynthetic pathway. The additional identifica
tion of the conserved dynamin-like GTPase Mgm1 (OPA1 in humans) as
a potential interacting partner of Fech supports earlier proteomic studies
in mammalian mitochondria [17,19]. Our recent study established that
the mgm1Δ mutant exhibits a marked defect in nuclear heme levels [46],
further supporting a model in which IM ultrastructure-related factors
like Mgm1 and MICOS may cooperate with Fech to facilitate delivery of
its substrate and/or distribution of its product.
4. Materials and Methods
4.1. Yeast strains, plasmids, and growth conditions –
Yeast strains used in this work were of the W303–1B genetic back
ground (MAT⍺ ade2-1 can1-100 his3-11,15 leu2-3 trp1-1 ura3-1), unless
specified otherwise. The ΔMICOS strain included in a Supplementary
figure lacks the genes MIC10, MIC60, MIC19, MIC27, MIC26, and
MIC12. Plasmids for wild-type and variant Hem15 and human ferro
chelatase expression in S. cerevisiae were produced as previously
described [61,62]. The HEM15 ORF with its 350-bp native promoter
region was subcloned into pRS424 and pRS426 vectors from the
pRS316-Hem15 plasmid described before [61]. This plasmid also served
as a template to generate a pRS426-Hem15 vector in which the HEM15
ORF is under the control of the heterologous MET25 promoter.
Fig. 7. Model for involvement of MICOS in heme
biosynthesis. IM-OM contacts formed by MICOS
may facilitate the transfer of intermediate porphyrin
precursors (purple crosses) across the mitochondrial
membranes into the matrix, thus ensuring optimal
delivery of substrate to Fech for synthesis of heme
(red crosses). Loss of Mic60/MICOS results in
accumulation of porphyrin intermediates and sub
sequent oxidative damage. See Discussion for addi
tional details. (For interpretation of the references to
color in this figure legend, the reader is referred to
the Web version of this article.)
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To generate a plasmid expressing Hem15-iFLAG, the mitochondrial
targeting sequence (MTS) of Hem15 (amino acid residues 1–31) with a
flanking region containing the FLAG epitope tag at the 3’-end was PCRamplified from the pRS426-Hem15 plasmid using primers 5’CGCGGATCCATGCTTTCCAGAACAATCCGTACACAAGGTTCCTTCCTAA
GAAGATCACAACTGACCATT-3’ and 3’-CTTGTCGTCATCGTCTTTG
TAGTCCTGCATGTTGAATGTAACCGAAAATGATCTTGTAATGGTCAGTT
GTGATCTTCT-5’. In a separate reaction, Hem15 excluding the MTS
(amino acid residues 31–393) containing the FLAG epitope tag at the 5’end was PCR amplified from the same plasmid using primers 5’-GACTA
CAAAGACGATGACGACAAGAATGCACAAAAGAGATCACCCACAGGAAT
TGTTTTGATGAACATGGGTGGC-3’ and 3’-GCGCTCGAGTCAAGTA
GATTCGTGATTGCCAAATACCAATGAAAGGTCCTTTACAGGATCATTGG
ACTT-5’. Gel-purified products of the reactions described above were
fused together by overlap extension PCR using 5’- CGCGGATC
CATGCTTTCCAGAACAATCCGTACACAAGGTTCCTTCCTAAGAAGATCA
CAACTGACCATT-3’ and 3’-GCGCTCGAGTCAAGTAGATTCGTGATTGCC
AAATACCAATGAAAGGTCCTTTACAGGATCATTGGACTT-5’ including
5’-BamHI and 3’-XhoI restriction sites, respectively. The obtained product
was cloned into pRS423 vector under the control of the MET25 promoter
and CYC1 terminator.
The pRS424-Rnr1 plasmid was generated by subcloning a 2.8-kbp
fragment
from
the
YEplac181-Rnr1
vector
[39].
The
pCM185-Mrs3-FLAG plasmid has been described previously [63]. All
plasmids were validated by DNA sequencing.
Depending on experiment, cells were cultured in yeast extractpeptone (YP) or synthetic complete (SC) media lacking nutrients
(amino acids or nucleotides) necessary to maintain plasmid selective
pressure [64] containing either 2% glucose, 2% galactose, or 2% glyc
erol/2% lactic acid mix as the carbon source. To culture heme
synthesis-deficient strains, cells were grown in the presence of either
hemin or Tween-80/ergosterol/methionine mix as described previously
[65,66]. Growth tests to assess respiratory capacity and quantify
hydrogen peroxide sensitivity were carried out as before [67,68], except
cells lacking functional Hem15 were cultured in 20 μM hemin. Cultures
used for growth tests were grown overnight (or two days in the case of
cells lacking functional Hem15) in SC media lacking relevant nutrients
to maintain plasmid selection then normalized to OD600 of 1 and spotted
onto SC plates with or without 20 μM hemin.

centrifugation at 4000 rpm for 5 min. Cells were then washed in 5 ml ice
cold water and re-centrifuged. Pellets were then resuspended on ice in 4
mL lysis buffer (50 mM Tris-MOPS, pH 8.0, 100 mM KCl, 1% sodium
cholate) with 40 μL fungal protease inhibitor cocktail (Sigma P-8215)
and transferred to 50-mL conical tubes. Glass beads (4 mL, 0.5 mm) were
then added, and cells were vortexed for 1 min at maximum speed fol
lowed by 1 min on ice, repeated for a total of 5 vortex cycles. Tubes
containing lysate and beads were then centrifuged at ~9000×g for 5
min. Supernatant was removed using a 1-mL pipette, taking care not to
disturb the pellet. The supernatant was then transferred to 2-ml micro
centrifuge tubes and further centrifuged at 15000×g for 10 min. Su
pernatant was transferred to fresh microcentrifuge tubes and stored on
ice for up to 2 h during measurements. Total protein concentration of
yeast lysate was measured via a NanoDrop spectrophotometer with 1 A
= 1 mg/mL setting. Heme and porphyrin analysis were carried out at the
University of Utah Center for Iron and Heme Disorders core facility as
previously described [11,17].
4.3. Hem15 activity assays Lysate volumes ranging from 0 to 200 μL were brought to a total
volume of 850 μL with lysis buffer in 3-mL glass tubes. Master mix (150
μL) consisting of 20 mM ferrous sulfate, ~1 mM protoporphyrin IX, and
33.3 mM β-mercaptoethanol was added to start the assay. Samples were
incubated in the dark at 37◦ C for 15 min. Heme produced in lysate ac
tivity assays was quantified by pyridine hemochromogen assay. To stop
the assay reactions and produce the pyridine hemochrome derivative, 1
mL 50% (v/v) pyridine:0.2 N NaOH solution was added to 1-mL assay
samples. Heme content was measured via differential spectra of oxidized
and reduced samples as described previously [69–71].
4.4. Variant construction, protein expression, purification, and X-ray
crystallography –
The Hem15 variant H235C was constructed using QuikChange sitedirected mutagenesis (Agilent) and verified by sequencing. His-tagged
mature wild-type and variant Hem15 were produced as previously
described [40,72]. In vivo ferrochelatase activity of the variant was
assessed by complementation and rescue of a strain of Escherichia coli
lacking functional ferrochelatase, ppfCΔ [73,74]. The H235C variant
protein was concentrated to ~400 μM and crystals were grown by
hanging drop with mother liquor composed of 0.1 M Bis-Tris pH 6.5,
25% PEG 3350 within 48 h.
All data sets were collected at the Advanced Photon Source and SERCAT on beamline 22-ID. Phases were obtained by using a monomer of
wild-type Hem15 (PDB ID 1LBQ) as a molecular replacement search
model. Molecular replacement was performed using the program CNS
[75]. Iterative rounds of model building and refinement were performed
with the programs COOT [76] and CNS, respectively. Data collection,
refinement statistic, and PDB ID for the H235C structure are listed in
Table SI. Structural representations were created using PyMol [77].

4.2. Heme and porphyrin analysis –
Total cellular porphyrin content was measured using a previously
described porphyrin fluorescence assay [44]. Briefly, 1 × 108 log-phase
cells were harvested, washed in sterile ultrapure water, resuspended in
500 μL of 20 mM oxalic acid and stored at 4◦ C overnight (16–18 h) in the
dark. The next day, 500 μL of 2 M oxalic acid was added to the cell
suspensions. Half the cell suspension was transferred to a heat block set
at 95◦ C and heated for 30 min to demetallate the heme iron to yield
fluorescent protoporphyrin IX. The other half of the cell suspension was
kept at room temperature for 30 min. All suspensions were centrifuged
for 2 min on a table-top microfuge at 21,000×g and the porphyrin
fluorescence spectra (excitation at 400 nm) or emission at 620 nm of
200 μL of each sample was recorded on a Synergy Mx multi-modal plate
reader using black Greiner Bio-one flat bottom fluorescence plates. The
"boiled" sample provides a measure of total heme and protoporphyrin IX
in cells. The "room temperature" sample provides a measure of total
protoporphyrin IX in cells. When the "room temperature" sample is
subtracted from the "boiled" sample, "total" cellular heme is revealed.
Concentrations of heme or protoporphyrin IX are derived from standard
curves of known concentrations of heme boiled in oxalic acid similarly
to the description above.
For high-resolution heme and porphyrin analysis, yeast cultures
(125 mL) were inoculated from a fresh culture at OD600nm of
0.003–0.009 and grown overnight at 37◦ C and 225 rpm shaking until
OD600nm= 1. One hundred mL of culture was harvested by

4.5. Mass spectrometry and data analysis –
Affinity purification and mass spectrometry were carried out as
described for human ferrochelatase [17], except 1% digitonin was used
to solubilize purified mitochondria. Subsequent analysis of candidate
hits against the CRAPome database (www.crapome.org) eliminated
known contaminants and non-specific interactors.
4.6. Mitochondrial isolation and assays –
Mitochondria-enriched fractions were isolated using established
protocols [78]. For ICP-MS measurements, mitochondrial fractions were
further purified using discontinuous 14%/22% Nicodenz gradients as
described [79]. Total mitochondrial protein concentrations were
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determined using the Coomassie Plus kit (Thermo Scientific). Proteins or
protein complexes were separated by SDS-PAGE, blue native
(BN)-PAGE, or continuous 12–50% sucrose density gradient ultracen
trifugation as previously described [67,80]. Aconitase specific activity
was determined as before [81].

Rip1 (provided by Dr. D. Winge), Mic60 (provided by Dr. N. Pfanner),
Aco1 (provided by Dr. R. Lill), and β-subunit of F1 ATP synthase (pro
vided by Dr. A. Tzagoloff). All antibodies were tested for reliability to
ensure specificity of detection.
Declaration of competing interest

4.7. Heme trafficking dynamics assay –
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Heme trafficking rates were monitored as previously described [46].
Briefly, in this three-step assay: 1) heme synthesis is first inhibited with
succinylacetone (SA) in sensor-expressing cells, 2) the block in heme
synthesis is then removed by resuspending cells into media lacking SA,
and 3) the time-dependent change in the heme occupancy of HS1 is
monitored. The fractional heme occupancy of the sensor can be deter
mined using previously established sensor calibration protocols [44].
The percent of sensor bound to heme (% Bound) is calculated by
determining the sensor eGFP/mKATE2 fluorescence ratio (R) under a
given test condition relative to the eGFP/mKATE2 fluorescence ratio
when the sensor is 100% (Rmax) or 0% (Rmin) bound to heme, as
described previously [44–46,82]. Rmin is determined by measuring the
HS1 eGFP/mKATE2 ratio in parallel cultures that are conditioned with
succinylacetone (SA), which inhibits the second enzyme in the heme
biosynthetic pathway, Pbgs [83], and Rmax can be determined by per
meabilizing cells and adding an excess of heme to saturate the sensor
[44]. Given HS1 is quantitatively saturated with heme in the cytosol,
nucleus, and mitochondria of WT yeast, Rmax is typically determined by
measuring the HS1 eGFP/mKATE2 ratio in parallel WT cultures grown
without SA [44].
Growth for the heme trafficking dynamics assay was accomplished
by culturing HS1-expressing cells with or without 500 μM SA (SigmaAldrich) in SC media lacking leucine. Triplicate 5-mL cultures were
seeded at an initial optical density of OD600nm = 0.01-0.02 (~2–4 x 105
cells/mL) and grown for 14–16 h at 30◦ C and shaking at 220 rpm until
cells reached a final density of OD600nm ~ 1.0 (~2 × 107 cells/mL). After
culturing, 1 OD (or ~2 × 107 cells) were harvested, washed twice with 1
mL of ultrapure water, and resuspended in 1 mL of fresh media. The cells
that were pre-cultured without SA provided HS1 Rmax values. The SAconditioned cells were split into two 500-μL fractions. One fraction
was treated with 500 μM SA to give HS1 Rmin values. The other fraction
was not treated with SA so that heme synthesis could be re-initiated to
give compartment-specific heme trafficking rates. HS1 fluorescence was
monitored on 200 μL of a 1 OD/mL (~2 × 107 cells/mL) cell suspension
using black Greiner Bio-one flat bottom fluorescence plates and a Syn
ergy Mx multi-modal plate reader. Fluorescence of eGFP (λexc. = 488 nm,
λem. = 510 nm) and mKATE2 (λexc. = 588 nm, λem. = 620 nm) was
recorded every 5 min for 4 h, with the plate being shaken at “mediumstrength” for 30 s prior to each read. Background fluorescence of cells
not expressing the heme sensors was recorded and subtracted from the
eGFP and mKATE2 fluorescence values.
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Supplemental Table
Table S1. Data collection and refinement statistics for yeast Hem15 H235C variant

Data Collection
Beamline
Space Group
Wavelength
Resolution Range (Å)
Outer Shell
Unique Observations
Completeness (%)
Rsym (%)b
CC ½
Redundancy
I/s

APS 22-ID
P212121
0.98
50.0-2.4
2.51-2.4
32,665
99.2(96.8)a
6.6(31)
0.99(0.72)
3.5(2.9)
17.7(2.9)

Refinement
Unit Cell (a, b, c) in Å
Protein Atoms
Solvent Atoms
Resolution Limits (Å)
Rcryst (%)
Rfree (%)
rmsd bonds (Å)
rmsd angles ( ° )
average B factor (Å2)
PDB ID code

49.9, 51.6, 287.3 ; a=g=b=90º
5675
66
50.0-2.4
23.2
29.6
0.009
1.1
45
7L78

a

Numbers in parentheses denote values for the outermost resolution shell. bRsym = ∑hkl[∑I(|Ihkl,I <Ihkl>|)]/∑hkl,I<Ihkl>, where Ihkl is the intensity of an individual measurement of the reflection
with indices hkl and <Ihkl> is the mean intensity of that reflection.

Supplemental Figures
Figure S1, related to Figure 1. Biochemical and structural analysis of Hem15 and its
H235C variant. (A) Indicated amounts of E. coli-expressed purified Hem15 along with 100 µg of
purified mitochondria from WT cells were analyzed by denaturing gel and immunoblotting with
anti-Hem15 antibody. The linear signal intensities were assessed by automated densitometry
and used to estimate the relative amount of endogenous Hem15. (B) Left: Steady-state levels of
Hem15 and loading control (porin) in mitochondria from hem15D cells overexpressing Hem15
(from the HEM15 promoter), the Hem15 variant H235C, or a vector control, analyzed by SDSPAGE and immunoblotting with respective antibodies. Right: Heme-dependence growth test of
these cells (and WT cells) spotted onto SC medium with or without 20 µM hemin and cultured
for 2 days at 28oC. (C) Ability to rescue E. coli ppfCD ferrochelatase mutant by yeast Hem15
WT and H235C variant and their ferrochelatase catalytic rate constant. Data are representative
of 3 biological replicates. (D) Absorbance spectra of E. coli-purified yeast Hem15 WT and
H235C variant, indicating that the WT Hem15 predominantly co-purifies with bound heme (Soret
lmax = 427 nm; dashed line), while the H235C variant co-purifies with bound PPIX (Soret lmax =
~410 nm). Spectra are representative of 3 biological replicates. (E) Crystal structures (2.4 Å) of
Hem15 WT and H235C variant showing views of the active site with the hydrogen-bonding
network (dashes) and key residues involved in catalysis (sticks representation).

Figure S2, related to Figure 2. Combined expression of RNR1 and HEM15 permits
respiratory growth of the hem15D mutant and results in stabilization of the mitochondrial
respiratory complexes III and IV. (A) Steady-state levels of Hem15 with loading control (porin)
in mitochondria of WT cells and hem15D cells with or without HEM15 overexpression from its
native promoter (HEM15 ↑) or the high-efficiency heterologous MET25 promoter (HEM15 ↑↑).

Samples were analyzed by SDS-PAGE and immunoblotting with indicated antibodies. (B) BNPAGE analysis of dodecyl-β-D-maltoside (DDM)-solubilized mitochondrial proteins from WT
cells or hem15D cells co-expressing the indicated combinations of the following plasmids: vector
control (-), Rnr1 (RNR1 ↑), Hem15 under the control of its native promoter (HEM15 ↑), and
Hem15 under the control of the high-efficiency heterologous MET25 promoter (HEM15 ↑↑).
Complexes were visualized by immunoblotting with the indicated antibodies (mon. Atp2 refers to
the monomeric protein). The heme-containing electron transport chain complexes III and IV, as
well as the non-heme complex V, are severely attenuated in hem15D cells regardless of Hem15
re-expression (compare lanes 2, 4, and 6), and these levels are restored to normal upon coexpression of RNR1 and HEM15 (lanes 5 and 7). (C) Heme-dependence growth test of Rnr1expressing hem15D cells harboring no other plasmids (-), vector control (vector), yeast
ferrochelatase (HEM15), or human ferrochelatase (FECH), assessed as described in Fig. 2B.

Figure S3, related to Figure 3. Generation of a functional Hem15-iFLAG construct and
steady-state levels of Hem15 in mic60D cells. (A) Schematic depiction of the Hem15-iFLAG
construct bearing an internal FLAG epitope tag. MTS, mitochondrial targeting sequence. (B)
Heme-dependence glucose growth test of WT and hem15D cells co-overexpressing RNR1 and
either vector control, untagged Hem15, or Hem15-iFLAG under control of the MET25 promoter,
assessed as in Fig. 2A. (C) Expression of Hem15-iFLAG in hem15D cells overexpressing RNR1
analyzed by SDS-PAGE and immunoblotting with anti-FLAG antibody (and anti-porin antibody
as a loading control). (D) Steady-state levels of indicated proteins in mitochondria from WT,
mic60D, and hem15D cells, visualized by SDS-PAGE and immunoblotting with indicated
antibodies.

Figure S4, related to Figure 5. Analysis of mitochondrial iron, iron-related proteins,
mitochondrial protein lipoylation, and porphyrin fluorescence in MICOS-deficient cells.
(A) Left: Elemental ICP-MS analysis of iron levels in gradient-purified mitochondria from WT and
mic60∆ cells expressing vector control or Hem15 under the heterologous MET25 promoter
(HEM15 ↑↑). Bars indicate the average and S.E.M (error bars) of 3 biological replicates. Right:
Steady-state levels of indicated proteins in gradient-purified mitochondria (pure mito.) analyzed
by SDS-PAGE immunoblot with appropriate antibodies. (B) Steady-state levels of indicated
proteins in mitochondria from the cells described in panel A analyzed by SDS-PAGE
immunoblot with appropriate antibodies. (C) Succinate dehydrogenase specific activity in
mitochondrial lysates from cells described in panel A. Bars indicate the average and S.D. (error
bars) of 3 biological replicates. (D) Left: Total porphyrin content of WT and mic60∆ cells cultured
with or without 500 µM succinylacetone (SA) in 2% glucose or 2% galactose measured by
porphyrin fluorescence assay. Data are mean ± S.D. of triplicate cultures. *p<0.01 (one-way
ANOVA with Bonferroni posthoc test). Right: Fluorescence spectra of steady-state total
porphyrinogens from oxalic acid-digested cell extracts (1×108 cells/mL) of the indicated cell
cultures. The data represent mean ± S.D. of independent triplicate cultures. (E) Steady-state
levels of two lipoylated mitochondrial proteins, pyruvate dehydrogenase subunits
dihydrolipoamide acetyltransferase (DLAT) and dihydrolipoyl succinyltransferase (DLST),
Hem15, Mic60 and porin measured in WT, mic60D, and ∆MICOS (lacking virtually all MICOS
subunits) cells and analyzed by SDS-PAGE immunoblot with appropriate antibodies.

Figure S5, related to Figure 5. Detailed analysis of identifiable porphyrin biosynthetic
precursors in MICOS-deficient cells. Indicated intermediate (4-, 5-, 6-, 7- and 8-COOH)
porphyrins, as derived from pathway intermediate porphyrinogens, were analyzed by UPLC.

Bars indicate average ± S.D. (error bars) of 4-5 biological replicates measured in technical
triplicates. Asterisks indicate a statistically significant difference by t-test (*p<0.05, **p<0.01).

Figure S6, related to Figure 6. Steady-state aconitase levels are unaffected in Hem15overexpressing mic60D cells. Steady-state levels of indicated proteins in mitochondria from
WT and mic60D cells expressing vector control or Hem15 under control of its native promoter
(HEM15 ↑) or the heterologous MET25 promoter (HEM15 ↑↑), analyzed by SDS-PAGE
immunoblot with appropriate antibodies. Asterisk indicates non-specific cross-reacting bands.
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